WO2012047017A3 - Dérivé 2,3-dihydro-isoindol-1-one et composition le comprenant - Google Patents

Dérivé 2,3-dihydro-isoindol-1-one et composition le comprenant Download PDF

Info

Publication number
WO2012047017A3
WO2012047017A3 PCT/KR2011/007370 KR2011007370W WO2012047017A3 WO 2012047017 A3 WO2012047017 A3 WO 2012047017A3 KR 2011007370 W KR2011007370 W KR 2011007370W WO 2012047017 A3 WO2012047017 A3 WO 2012047017A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
kinase activity
isoindol
dihydro
derivative
Prior art date
Application number
PCT/KR2011/007370
Other languages
English (en)
Korean (ko)
Other versions
WO2012047017A2 (fr
Inventor
홍용래
이미정
김정미
홍장원
장호진
박수봉
이휘성
최종류
노성구
조중명
Original Assignee
크리스탈지노믹스(주)
한국보건산업진흥원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크리스탈지노믹스(주), 한국보건산업진흥원 filed Critical 크리스탈지노믹스(주)
Publication of WO2012047017A2 publication Critical patent/WO2012047017A2/fr
Publication of WO2012047017A3 publication Critical patent/WO2012047017A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

La présente invention concerne une composition pharmaceutique pour le traitement, le soulagement ou la prévention de maladies associées à une activité kinase anormale ou déréglée, la composition comprenant un composé représenté par la formule chimique 1 et son sel, hydrate, promédicament ou solvat pharmaceutiquement acceptable. Le composé et la composition de la présente invention inhibent divers types d'activité de protéines kinases, et peuvent donc être utilisés de façon avantageuse dans le traitement, le soulagement ou la prévention de maladies associées à une activité kinase anormale ou déréglée.
PCT/KR2011/007370 2010-10-05 2011-10-05 Dérivé 2,3-dihydro-isoindol-1-one et composition le comprenant WO2012047017A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38995010P 2010-10-05 2010-10-05
US61/389,950 2010-10-05

Publications (2)

Publication Number Publication Date
WO2012047017A2 WO2012047017A2 (fr) 2012-04-12
WO2012047017A3 true WO2012047017A3 (fr) 2012-05-31

Family

ID=45928221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/007370 WO2012047017A2 (fr) 2010-10-05 2011-10-05 Dérivé 2,3-dihydro-isoindol-1-one et composition le comprenant

Country Status (1)

Country Link
WO (1) WO2012047017A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2571883B1 (fr) 2010-05-20 2015-01-07 Array Biopharma, Inc. Composés macrocycliques en tant qu'inhibiteurs de kinase trk
RU2671847C2 (ru) * 2012-12-28 2018-11-07 Кристалдженомикс, Инк. Производные 2,3-дигидро-изоиндол-1-она и способы их применения в качестве ингибиторов тирозинкиназы брутона
PL3322706T3 (pl) 2015-07-16 2021-07-19 Array Biopharma, Inc. Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret
KR101691954B1 (ko) * 2016-04-26 2017-01-02 고려대학교 산학협력단 신규 n-아실유레아 유도체 및 이를 함유하는 심혈관질환의 예방 또는 치료용 조성물
CN105859638B (zh) * 2016-04-28 2018-07-17 西安交通大学 一种具有抗肿瘤活性的环丁二酰胺化合物及其制备方法和应用
CN105924387A (zh) * 2016-04-28 2016-09-07 西安交通大学 一种具有抗肿瘤活性的双芳基脲化合物及其制备方法和应用
CN105906568A (zh) * 2016-04-28 2016-08-31 西安交通大学 一种具有抗肿瘤活性的环丙二酰胺化合物及其制备方法和应用
CN105924403B (zh) * 2016-04-28 2018-07-17 西安交通大学 一种具有抗肿瘤活性的环丙二酰胺类化合物及其制备方法和应用
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (fr) 2017-01-18 2018-07-26 Array Biopharma, Inc. Inhibiteurs de ret
EP3571203B1 (fr) 2017-01-18 2023-06-07 Array BioPharma Inc. Composés de pyrazolo[1,5-a]pyrazine substitués utilisés en tant qu'inhibiteurs de la kinase ret
CN110234645A (zh) * 2017-01-25 2019-09-13 巴斯夫欧洲公司 制备卞型酰胺的方法
CN110621665A (zh) * 2017-02-21 2019-12-27 艾普托斯生物科学公司 用于治疗患有恶性血液病的患者的方法
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
WO2019134662A1 (fr) * 2018-01-03 2019-07-11 南京明德新药研发股份有限公司 Composé hétérocyclique en tant qu'inhibiteur de csf -1 r et son utilisation
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143994A1 (fr) 2018-01-18 2019-07-25 Array Biopharma Inc. Composés de pyrazolyl[4,3-c]pyridine substitués utilisés en tant qu'inhibiteurs de la kinase ret
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
AU2019387508A1 (en) * 2018-11-30 2021-06-10 Aptose Biosciences Inc. Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
WO2022212893A1 (fr) 2021-04-02 2022-10-06 Biogen Ma Inc. Méthodes de traitement combiné de la sclérose en plaques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161648A1 (en) * 2005-10-14 2007-07-12 Hughes Terry V Substituted dihydro-isoindolones useful in treating kinase disorders
US20090054407A1 (en) * 2005-04-19 2009-02-26 Kyowa Hakko Kogyo Co., Ltd. Nitrogen-containing heterocyclic compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054407A1 (en) * 2005-04-19 2009-02-26 Kyowa Hakko Kogyo Co., Ltd. Nitrogen-containing heterocyclic compound
US20070161648A1 (en) * 2005-10-14 2007-07-12 Hughes Terry V Substituted dihydro-isoindolones useful in treating kinase disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUGHES, T. V. ET AL.: "7-[1H-Indol-2-yl]-2,3-dihydro-isoindol-1-ones as dual Aurora-A/ VEGF-R2 kinase inhibitors: Design, synthesis, and biological activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, no. 18, 2008, pages 5130 - 5133, XP025407688, DOI: doi:10.1016/j.bmcl.2008.07.090 *

Also Published As

Publication number Publication date
WO2012047017A2 (fr) 2012-04-12

Similar Documents

Publication Publication Date Title
WO2012047017A3 (fr) Dérivé 2,3-dihydro-isoindol-1-one et composition le comprenant
WO2010108074A3 (fr) Inhibiteurs de pi3 kinase
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
EP2650293A8 (fr) Composé de [1,2,4]triazolo[4,3-b][1,2,4]triazine, son procédé de préparation et son utilisation
WO2014151871A3 (fr) Inhibiteurs de jak2 et alk2 et leurs procédés d'utilisation
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
WO2012162254A8 (fr) Inhibiteurs de l'activité lrrk2 kinase
TR201906936T4 (tr) Protein kinaza yönelik inhibitör aktiviteye sahip tiyenopirimidin türevleri.
WO2012048129A3 (fr) Inhibiteurs de kinase de type polo
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
MX2021011563A (es) Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
WO2011014795A3 (fr) Composés et compositions pouvant servir d'inhibiteurs de la kinase syk
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
WO2012017239A3 (fr) Composés chimiques
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2013188273A8 (fr) Composition pharmaceutique ophtalmique topique contenant de l'axitinib
WO2013188283A8 (fr) Composition pharmaceutique ophtalmique topique contenant du sunitinib
WO2008131946A3 (fr) Dérivés d'amide substitués
WO2013188268A8 (fr) Composition pharmaceutique ophtalmique topique contenant du pazopanib
WO2009094560A3 (fr) Thiénopyranones en tant qu'inhibiteurs de kinase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11830902

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11830902

Country of ref document: EP

Kind code of ref document: A2